FDAer Resigns Over Plan B; Senators Seek Results Of GAO Investigation
This article was originally published in The Tan Sheet
Executive Summary
FDA Office of Women's Health Director Susan Wood is resigning over the agency's handling of Barr Labs' application to switch its Plan B emergency contraceptive over-the-counter
You may also be interested in...
Opill AdCom Delay Not Unusual – Will Evaluation Of US OTC Switch Proposal Continue In The Norm?
Whether FDA handling of HRA Pharma’s OTC switch NDA for 0.075-mg norgestrel continues along normal arc is question which prompts concerns. “I hope that they don't make the same mistakes that were made back on the Plan B,” says Susan Wood, an associate professor at George Washington University School of Public Health and a former FDA office director.
Like Plan B, Approval For OTC Daily Oral Contraceptives In US Could Be An 'Adventure’
It was only after prolonged litigation led a federal judge in 2013 to order FDA not to allow political interference with its science-based decisions that Plan B and generic equivalents became available OTC without age restrictions. “Hopefully, all I can say, it won't happen again,” says reproductive rights advocate Kirsten Moore.
Plan B Lightning May Strike Again: Complying Will Not End Political Storm
Perpetual political lightning rod - and emergency contraceptive - Plan B has another chance to draw strikes to FDA as the agency has chosen to comply with a court ruling ordering it to reconsider whether the drug should be available in a truly over-the counter setting